Pharmafile Logo
Pharmafocus logo
Advanced Search

UCB

Showing 15 posts of 76 posts found.

Representing medium-sized pharma

September 16, 2010
Sales and Marketing European Medicines Group, UCB

UCB’s Matthew Speers is the new chairman of the European Medicines Group, which represents European-owned pharma companies in the UK. …

Feature

New products help lift UCB

August 3, 2010
Sales and Marketing 2010 financials, Q2, UCB

UCB’s newer products showed impressive growth in the first six months of this year, helping keep the Belgium-based biopharma firm’s …

News
Matthew_Speers

UCB’s Speers to lead European Medicines Group

July 19, 2010
Sales and Marketing European Medicines Group, UCB, appointment, sales and marketing

UCB Pharma’s managing director Matthew Speers has been elected chair of the European Medicines Group, taking over from Nigel Brooksby …

Appointment

UCB’s new lupus treatment promising

June 17, 2010
Research and Development Benlysta, Lupus, UCB, epratuzumab

A new monoclonal antibody treatment for lupus has shown promise in phase II trials, according to UCB. The biopharmaceutical company …

News

UCB’s Kola joins Astex board

June 5, 2010
Research and Development Astex, UCB, appointment, research and development

Dr Ismail Kola has joined the board of directors at UK biotech company Astex Therapeutics. Astex’s non-executive chairman Peter Fellner …

Appointment

Slow recovery expected for epilepsy market

May 27, 2010
Sales and Marketing Datamonitor, Keppra, UCB, epilepsy

The global market for epilepsy treatments is expected to make a slow recovery after a wave of patent expiries from …

News

UCB’s Roch Doliveux joins Innovative Medicines Initiative board

May 19, 2010
Research and Development UCB, appointment, research and development

UCB’s chief executive Roch Doliveux has joined the governing board of the Innovative Medicines Initiative. The IMI is a public-private …

Appointment
UCB

Generic Keppra hits UCB sales

March 3, 2010
Sales and Marketing 2009 financials, Keppra, UCB

UCB’s sales fell 13% in 2009 as the pharma company faced the first full year of generic competition in the …

News
Blog footer

Digital Pharma: UCB’s online epilepsy community

February 8, 2010
Medical Communications, Research and Development PatientsLikeMe, UCB, community, digital pharma, digital pharma research, patient information

UCB has launched an online community for US epilepsy patients to record ‘real-world’ experiences of the condition. In addition to …

Feature

Patient access scheme secures NICE approval for Cimzia

January 22, 2010
Sales and Marketing Cimzia, NICE, UCB, rheumatoid arthritis

UCB Pharma’s Cimzia has been recommended by NICE to treat rheumatoid arthritis – but only if a patient access scheme …

News

UCB and Novartis expand alliance in Germany

September 1, 2009
Sales and Marketing Germany, Novartis, UCB

UCB and Novartis have extended their partnership in Germany with a new licensing deal for the cardiovascular and diabetes drug …

News

UCB in ‘dynamic mode’ as work begins at new biologics research centre

July 31, 2009
Research and Development UCB, biologics

 UCB has opened its new biologics research centre in the UK, marking an investment of £25 million for the growing …

Feature
UCB's new biologics research centre in Slough

UCB opens new UK biologics research centre

July 8, 2009
Research and Development UCB

 UCB has officially opened its new biologics research centre in the UK, representing an investment of £25 million for the …

News

Working Life: Andrew Clark

March 13, 2009
Research and Development, Sales and Marketing UCB, library

How did you find your way into your current role? On return from a working holiday to New Zealand I …

Feature

Making a sales pitch in the ‘war for talent’

March 10, 2009
Business Services UCB, recruitment

When I joined Celltech (now part of UCB) over 20 years ago it was difficult to attract candidates who valued …

Feature

Latest content

FDA approves Amgen’s Imdelltra for extensive-stage small cell lung cancer

May 17, 2024

AstraZeneca shares results from phase 3 trial of COVID-19 prevention drug

May 17, 2024

GSK pledges £45m to Fleming Initiative to fight AMR

May 16, 2024

NeuroSense partners with PhaseV on upcoming phase 3 ALS trial

May 16, 2024

AstraZeneca adds new heart failure target through collaboration with BenevolentAI

May 15, 2024